BrightInsight today announced a new investment round of $13 million from existing and new investors including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners. This new capital will accelerate development of BrightInsight's AI-enabled medication persistence and adherence solutions and enable rapid scalability of high-impact programs, such as the Patient App from its collaboration with Sanofi and their partner, Regeneron, across a broad range of diseases and therapies globally.

BrightInsight is the trusted partner and de-facto platform for top biopharma compliant digital health solutions. For life sciences companies pursuing digital transformation, the company offers the leading technology to rapidly develop, launch, and scale digital solutions. BrightInsight's cloud-based platform is the foundation for patient companion apps, digital-first patient support programs (PSP) and Software as a Medical Device (SaMD) solutions to improve medication persistence and adherence.